Important safety considerations : These medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
In McKenzies case, Jack prescribed the weight-loss drug Wegovy, which in late 2022 was approved for use in U.S
Weight loss outcomes depend on medication adherence, lifestyle factors, and individual response
[19] [3] Healthcare professionals should discuss these considerations with all women of reproductive age with PCOS who are starting these medications
However, brand-name medications are currently available, and compounding is only allowed when the patient needs a customized dosage or formulation that is not commercially available
it works, it has some side effects